35 results about "Ventricular tachycardia" patented technology

The invention relates to a ventricular tachycardia and ventricular fibrillation prediction method based on multi-modal clinical data and related equipment. The method comprises the following steps: acquiring structured clinical data and unstructured clinical data of a target patient; preprocessing the structured clinical data and the unstructured clinical data; converting the pre-processed structured clinical data and the pre-processed unstructured clinical data into embedded vectors to obtain structured clinical features and unstructured clinical features; fusing the structured clinical features and the unstructured clinical features based on a bidirectional attention mechanism and a dynamic gating fusion mechanism to obtain multi-modal fusion features; time sequence features are extracted from the multi-modal fusion features through time sequence modeling; and performing ventricular tachycardia and ventricular fibrillation risk prediction according to the time sequence characteristics to obtain a ventricular tachycardia and ventricular Structured and unstructured clinical data are effectively integrated, the multi-modal time sequence prediction model is established, and the prediction accuracy of the ventricular tachycardia and ventricular fibrillation is remarkably improved.

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg / kg bodyweight over a duration of up to 60 minutes can be administered and / or a maintenance dose of 0.1 to 10 μg / kg / hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and / or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and / or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

Ventricle-from-atrium (VfA) devices, systems, and methods may be configured to detect a tachyarrhythmia. For in-stance, an atrial event rate may be compared to a ventricular rate to determine whether a patient's heart is undergoing a tachyarrhythmia. Further, it may be determined whether the tachyarrhythmia is a supraventricular tachycardia or ventricular tachycardia prior to delivering therapy to treat the tachyarrhythmia.

A method includes applying pacing to ventricle of heart of patient from multiple electrode locations over circumference of multi-electrode catheter area. Cardiac signals are received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations among the received signals. Based on calculated correlations, the area is checked if it includes an arrhythmogenic location identified with predefined sufficient spatial resolution. If the resolution is insufficient, sub-area to pace is defined. Subsequent pacing is applied to ventricle from multiple electrode locations over a circumference of the sub-area. Subsequent cardiac signals are received in response to the subsequent pacing. Subsequent correlations among the subsequent received signals are calculated. Based on the subsequent correlations, it is ascertained whether the arrhythmogenic location is found in the sub-area. If an arrhythmogenic location is found with sufficient spatial resolution, the identified arrhythmogenic location is indicated to user.

The invention relates to a construction method and application of a spontaneous and persistent ventricular tachycardia animal model, in particular to a spontaneous and persistent ventricular tachycardia rat model based on MYL4 gene defect and myocardial infarction induction. The model is constructed by utilizing the synergistic effect of double pathological factors of MYL4 gene conserved gene defects and acquired myocardial infarction, the induction rate of the model is greater than or equal to 90%, the spontaneous duration time reaches 1-3 min, and the method is obviously superior to an existing construction method for inducing the spontaneous and continuous ventricular tachycardia model. The model can simulate the pathophysiological process of ventricular tachycardia after human MYL4 gene related cardiovascular diseases combined with myocardial infarction, provides general technical support for ventricular arrhythmia pathogenesis research, drug screening and medical instrument research and development, and has wide scientific research and clinical transformation value.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

A system includes a catheter, an electrocardiogram (ECG) system, and a processor. The catheter is configured to apply pacing to a given tissue location inside a ventricle of a heart of a patient. The ECG system is configured to acquire a set of ECG signals generated in response to the pacing, wherein electrodes of the ECG system attached to the patient define respective directions in space with respect to an origin located in the heart. The processor is configured to (i) compute a set of respective signal differences between the acquired set of ECG signals and a reference set of ECG signals, (ii) compute a set of corresponding deviation vectors along the respective directions in the space, the deviation vectors having magnitudes corresponding to the respective signal differences, (iii) using the deviation vectors, compute a direction vector from the given location to a new ventricle location at which to apply the pacing, and (iv) indicate the computed direction vector to a user.

The system described herein includes a tool that has been developed for the interactive planning of therapies (e.g., ablation therapies such as RA in the treatment of VT or catheter- based therapies, among many others) by accurately registering all treatment planning images into the same frame-of-reference, to enable physician interaction with different image visualizations of these registered images, including ablation target selection, to provide an environment that facilitates the efficient and accurate exchange of knowledge between physicians. The proposed tool is provided to increase access, expedite delivery, and improve target accuracy for various therapies, including the non-limiting example described below which provides an innovative non-invasive VT ablation therapy.

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

Embodiments of a wearable cardioverter defibrillator (WCD) system include a support structure for wearing by an ambulatory patient, a posture detector and at least one processor. When worn, the support structure maintains electrodes on the patient's body, and using the posture detector and the patient's ECG received via the electrodes, the processor determines the patient's posture, formulates posture-based templates of QRS complexes, and the patient's heart rate. The processor can use these determinations to distinguish between VT and SVT and make no-shock, and shock decisions.

The invention relates to identification of ventricular tachycardia (VT) targets by selective pacing. A method includes applying pacing to a ventricle of a heart of a patient from a plurality of electrode locations on a circumference of a multi-electrode catheter region. A cardiac signal is received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations between the received signals. Based on the calculated correlation, it is checked whether the region includes an arrhythmic location identified at a predefined sufficient spatial resolution. If the resolution is insufficient, the sub-region to be paced is defined. Subsequent pacing is applied to the ventricle from a plurality of electrode locations on the circumference of the sub-region. A subsequent cardiac signal is received in response to the subsequent pacing. A subsequent correlation between the subsequently received signals is calculated. Based on the subsequent correlations, it is determined whether to find the arrhythmic location in the sub-region. If an arrhythmic location is found with sufficient spatial resolution, the identified arrhythmic location is indicated to the user.

A physiological monitoring system collects electrocardiogram (“ECG”) data from through monitoring sensors via a sensor interface. A machine learning model identifies characteristics of the ECG data that may be attributable to a cardiovascular device used by the patient. At least one normal ECG template for the individual patient is created and continuously updated by the machine learning model. Abnormal ECG data sets are analyzed using knowledge-based beat classifiers to identify specific arrhythmias. A data structure stores responses to the specific arrhythmias based on their likely effects on the patient. For example, the response to a dangerous arrhythmia may be an emergency alarm, while the response to a temporary arrhythmia quickly corrected by the patient's pacemaker may be a non-urgent message or a note to file.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

A system for VT localization comprises an electrocardiograph (ECG) device for detecting electrical signals of a ventricular fibrillation event in a patient and producing ECG data, a localizer, and a display device. The localizer comprises a memory and a processor, the memory storing a model and one or more parameters of the model. The memory further stores instructions that when executed by the processor cause the processor to receive the ECG data, and generate a determination indicating whether a detected VT signal arose from an endocardial surface or epicardial surface based on signal averaged waveform for each of the leads. The display device is configured to output the determination, which can also be communicated to follow-on provider systems.

An ambulatory medical device configured to be worn on a patient's body includes at least one electrocardiogram (ECG) electrode configured to sense cardiac activity, at least one acoustic sensor configured to detect one or more heart sounds, and at least one processor. The at least one processor is configured to implement a cardiopulmonary function analyzer to detect a suspected tachyarrhythmia based on an analysis of ECG signal(s) and verify the suspected tachyarrhythmia as a ventricular tachycardia (VT) event by analyzing acoustic signal(s) to distinguish the VT event from a supraventricular tachycardia (SVT) event. Said analysis includes determining an intensity and / or a beat-to-beat variability of a first heart sound (S1). The at least one processor verifies the suspected tachyarrhythmia as the VT event when the intensity of the S1 sound is below a predetermined intensity threshold or when the beat-to-beat variability of the S1 sound is above a predetermined variability threshold.

To evaluate electrical propagation in a heart.SOLUTION: A method for evaluation of electrical propagation in the heart includes receiving a pacing signal applied to a heart of a patient, the pacing signal including a normal sequence and shorter abnormal pacing stimuli. A responsive cardiac signal is received, which is sensed by electrodes at a location in the heart and on a body surface of the patient. A model response is found and annotated from evoked potentials caused by the normal pacing stimuli. A correlation is made between the model responses along the different signal sections to find and calculate a normal time delay and a decremental time delay between the pacing stimuli and respectively resulting evoked potentials at a tissue location. A time difference is calculated, between the normal time delay and the decremental time delay. An EP map of at least a portion of the heart is presented to a user, with a graphical indication of the time difference presented at the tissue location.SELECTED DRAWING: Figure 1

The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

The present invention provides a pulsed electric field cardiac ablation depth evaluation device, method, equipment, and medium. The device includes a switch switching module, a timer, an impedance measurement module, an ablation depth processing unit, and an ablation depth display module. The evaluation device and method can provide an ablation depth evaluation result 5 minutes after treatment, can complete ablation evaluation during the operation, has significant time advantages, and has good real-time performance. Through the impedance measurement module and the ablation depth processing unit, the ablation depth can be accurately evaluated and displayed in a three-dimensional image, which is convenient for doctors to quickly judge the surgical treatment process and has a high degree of accurate quantification. The device and its evaluation method can be used in combination with various ablation catheters, and are applicable to the treatment scenarios of atrial fibrillation in shallow tissues and ventricular tachycardia in deeper tissues, with strong applicability.

This disclosure generally relates to systems, devices, and methods for initiating or inhibiting noise reversion pacing therapy based on a morphology analysis to determine whether monitored cardiac electrical activity is indicative of a ventricular tachycardia / ventricular fibrillation (VT / VF). Specifically, if the morphology analysis indicates that a VT / VF episode is occurring, then noise reversion pacing therapy is inhibited.

The invention discloses a real-time monitoring and arrhythmia early warning system for electrocardiogram data of a patient in the department of cardiology. The system comprises a signal acquisition module, a wavelet-adaptive hybrid filtering module, a multi-scale feature extraction module, a depth space-time classifier, a risk dynamic evaluation module and a high-precision anti-interference module, motion noise and baseline drift are effectively suppressed, and key waveform characteristics of P waves, QRS waves and the like can still be accurately captured in a strong interference environment. And multi-dimensional feature fusion: in combination with time-frequency domain features, nonlinear sample entropy and dynamic cardiac beat period analysis, the recognition resolution of complex arrhythmia such as atrial fibrillation and ventricular velocity is remarkably improved.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The invention relates to pacing ventricular tachycardia detection. A physiological monitoring system collects electrocardiogram ("ECG") data from a through-monitoring sensor via a sensor interface. The machine learning model identifies characteristics of ECG data attributable to a cardiovascular device used by a patient. The machine learning model creates and persistently updates at least one normal ECG template for an individual patient. The abnormal ECG dataset is analyzed using a knowledge-based heartbeat classifier to identify a particular arrhythmia. The data structure stores a response to the particular arrhythmia based on the possible impact of the particular arrhythmia on the patient. For example, the response to dangerous arrhythmias may be an emergency alert, while the response to transient arrhythmias quickly corrected by the patient's pacemaker may be a non-urgent message or annotation to be archived.

To provide a cardiopulmonary resuscitation (CPR) support device that can estimate a cause of cardiopulmonary arrest other than ventricular fibrillation and ventricular tachycardia during CPR using an automated external defibrillator. [Solution] A cardiopulmonary resuscitation support device that is built into an automated external defibrillator or used in combination with an automated external defibrillator, and is equipped with an estimation means for estimating a cause of cardiopulmonary arrest other than ventricular fibrillation and ventricular tachycardia during cardiopulmonary resuscitation.

To provide a method for evaluation of electrical propagation in the heart.SOLUTION: A method includes applying pacing to ventricle of heart of patient from multiple electrode locations over circumference of multi-electrode catheter area. Cardiac signals are received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations among the received signals. Based on calculated correlations, the area is checked if it includes an arrhythmogenic location identified with predefined sufficient spatial resolution. If the resolution is insufficient, sub-area to pace is defined. Subsequent pacing is applied to ventricle from multiple electrode locations over a circumference of the sub-area. Subsequent cardiac signals are received in response to the subsequent pacing. Subsequent correlations among the subsequent received signals are calculated. Based on the subsequent correlations, it is ascertained whether the arrhythmogenic location is found in the sub-area. If an arrhythmogenic location is found with sufficient spatial resolution, the identified arrhythmogenic location is indicated to user.SELECTED DRAWING: Figure 1